{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-23-005593","form_type":"8-K","ticker":"ZVRA","cik":"0001434647","company_name":"ZEVRA THERAPEUTICS, INC.","filed_at":"2023-03-07T23:59:59+00:00","discovered_at":"2026-05-14T18:03:44.965565+00:00","generated_at":"2026-06-18T09:35:31.803709+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Zevra reports Q4 net loss $9.0M ($0.26/sh); cash $102.9M; arimoclomol NDA resubmission on track for Q3 2023","bullets":["Q4 net revenue $2.3M (vs $2.6M in Q4 2021); net loss ($9.0M) or ($0.26)/share vs ($2.7M)/($0.08).","FY 2022 net revenue $10.5M (down from $28.7M); net loss ($41.5M) or ($1.20)/share vs ($62.9M)/($2.11) in 2021.","Cash, cash equivalents and investments $102.9M as of Dec 31, 2022; cash runway extended into 2026.","Arimoclomol NDA resubmission for NPC anticipated as early as Q3 2023.","KP1077 Phase 2 trial for IH: interim data expected as early as Q3 2023, top-line by year-end 2023."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-23-005593","json":"https://secwatch.observer/filing/0001437749-23-005593.json","markdown":"https://secwatch.observer/filing/0001437749-23-005593.md","text":"https://secwatch.observer/filing/0001437749-23-005593.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1434647/000143774923005593/0001437749-23-005593-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1434647/000143774923005593/kmph20221130_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-18T09:35:31.803709+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"48c58860e0ffead42fad2a0f45c8b7c59ef9ea82","claim":"ZEVRA THERAPEUTICS, INC. reported fourth quarter and fiscal year ended December 31, 2022 results: revenue $2.3 million, net income ($9.0) million, or ($0.26) per basic and diluted share, EPS ($0.26) per basic and diluted share.","evidence_excerpt":"Page 3 Overview of Fourth Quarter (Q4) and Full-Year (FY) 2022 Financial Results: Net revenue for Q4 2022 was $2.3 million, as compared to Q4 2021 net revenue of $2.6 million. Q4 2022 net revenue was primarily driven by ongoing reimbursements received from the French early access program for arimoclomol, AZSTARYS® royalty revenues and consulting fees.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1434647/000143774923005593/0001437749-23-005593-index.htm","confidence":1.0,"family_label":"Earnings Releases","details":[{"label":"Period","value":"fourth quarter and fiscal year ended December 31, 2022"},{"label":"Revenue","value":"$2.3 million"},{"label":"Net income","value":"($9.0) million, or ($0.26) per basic and diluted share"},{"label":"EPS","value":"($0.26) per basic and diluted share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}